Insulin resistance: The adipose tissue in the focus;Inzulinrezisztencia - Célkeresztben a zsírszövet

Orvosi Hetilap

Volumn 146, Issue 43, 2005, Pages 2199-2207

  Urich, Elemér ^a,b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b NONE   (Hungary)

Author keywords

11 hydroxysteroid dehydrogenase type 1; Adipocyte hypertrophy and hyperplasia; Cushing syndrome; Insulin resistance; Metabolic syndrome; Obesity; PPAR ; Thiazolidinedione; Type 2 diabetes; Visceral and subcutaneous adipose tissue

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; 2,4 THIAZOLIDINEDIONE; 2,4-THIAZOLIDINEDIONE; ANTIDIABETIC AGENT;

ADIPOSE TISSUE; CARDIOVASCULAR RISK; CUSHING SYNDROME; DISEASE COURSE; DRUG EFFECT; HUMAN; INSULIN RESISTANCE; LIPODYSTROPHY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; REVIEW; THERAPY EFFECT; ADIPOCYTE; HYPERPLASIA; HYPERTROPHY; METABOLISM; PATHOLOGY;

ADIPOCYTES; ADIPOSE TISSUE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERPLASIA; HYPERTROPHY; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; OBESITY; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 33644824598     PISSN: 00306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Abate, N., Garg, A., Coleman, R. és mtsai: Prediction of total subcutaneous abdominal, intraperitoneal, and retroperitoneal adipose tissue masses in men by a single axial magnetic resonance imaging slice. Am. J. Clin. Nutr., 1997, 65, 403-408.
2. Abate, N., Garg, A., Peshock, R. M. és mtsai: Relationships of generalized and regional adiposity to insulin sensitivity in men. J. Clin. Invest., 1995, 96, 88-98.
3. Arner, P.: Free fatty acids-do do they play a central role in type 2 diabetes? Diabetes Obes Metab., 2001, 3. Suppl. 1.: S11-19.
4. Arner, P.: The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol. Metab., 2003, 14, 137-145.
5. Beltowski, J.: Adiponectin and resistin-new hormones of white adipose tissue. Med. Sci. Monit., 2003, 9, RA, 55-61.
6. Berger, J., Moller, D. E.: The mechanisms of action of PPARs. Annu. Rev. Med., 2002, 53, 409-435.
7. Berger, J., Tanen, M., Elbrecht, A. és mtsai: Peroxisome proliferator-activatcd receptor-gamma ligands inhibit adipocyte 11beta - hydroxysteroid dehydrogenase type 1 expression and activity. J. Biol. Chem., 2001, 20, 12629-12635.
8. Boden, G., Shulman, G. I.: Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur. J. Clin. Invest., 2002, 32 (Suppl. 3.), 14-23.
9. Bujalska, I. J., Kumar, S., Stewart, P. M.: Does central obesity reflect " Cushing's disease of the omentum"? Lancet, 1997, 349, 1210-1213.
10. Camp, H. S., Ren, D., Leff, T.: Adipogenesis and fat-cell function in obesity and diabetes. Trends Mol. Med., 2002, 8, 442-447.
11. Carey, D. G., Cowin, G. J., Galloway, G. J. és mtsai: Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients (corrected). Obes Res., 2002, 10, 1008-1015.
12. Carey, D. g., Jenkins, A. B., Campbell, L. V. és mtsai: Abdominal fat and insulin resistance in normal and overweight women: Direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes, 1996, 45, 633-638.
13. Collins, A. R.: Pleiotropic vascular effects of PPARgamma ligands. Drug News Perspect., 2003, 16, 197-204.
14. Dallman, M. F., la Fleur, S. E., Pecoraro, N. C. és mtsai: Minireview: glucocorticoids-food intake, abdominal obesity, and wealthy nations in 2004. Endocrinology. 2004, 145, 2633-2638.
15. Danforth, E. Jr.: Failure of adipocyte differentiation causes type II diabetes mellitus? Nat Genet., 2000, 26, 13-13.
16. Day, C.: Thiazolidinediones: a new class of antidiabetic drugs. Diabet. Med., 1999, 16, 179-192.
17. Folsom, A. R., Kaye, S. A., Sellers, T. A. és mtsai: Body fat distribution and 5-year risk of death in older women. JAMA, 1993, 269, 483-487.
18. Fontbonne, A., Thibult, N., Eschwege, E. és mtsai: Body fat distribution and coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes mellitus: the Paris Prospective, Study, 15-year follow-up. Diabetologia, 1992, 35, 464-468.
19. Frayn, K. N.: Visceral fat and insulin resistance-causative or correlative? Br. J. Nutr., 2000, 83, (Suppl. 1.) S71-77.
20. Fujioka, S., Matsuzawa, Y., Tokunaga, K. és mtsai: Improvement of glucose and lipid metabolism associated with selective reduction of intra-abdominal visceral fat in premenopausal women with visceral fat obesity. Int. J. Obes., 1991, 15, 853-859.
21. Gavrilova, O., Marcus-Samuels, B., Graham, D. és mtsai: Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J. Clin. Invest., 2000, 105, 271-278.
22. Girod, J. P., Brotman, D. J.: The metabolic syndrome as a vicious cycle: does obesity beget obesity? Med Hypotheses, 2003, 60, 584-589.
23. Guo, Z., Hensrud, D. D., Johnson, C. M. és mtsai: Regional postprandial fatty acid metabolism in different obesity phenotypes. Diabetes, 1999, 48, 1586-1592.
24. Hausman, D. B., Di-Girolamo, M., Bartness, T. J. és mtsai: The biology of white adipocyte proliferation. Obes Rev., 2001, 2, 239-254.
25. Kalmijn, S., Curb, J. D., Rodriguez, B. L. és mtsai: The association of body weight and anthropometry with mortality in elderly men: the Honolulu Heart Program. Int. J. Obes Relat. Metab. Disord., 1999, 23, 395-402.
26. Kelley, D. E., McKolanis, T. M., Kelley, C. A.: Comparative effects of rosiglitazone and metformin on fatty liver and visceral adiposity in type 2 diabetes mellitus. Diabetes, 2002, 51 (Suppl. 2.), A35.
27. Klein, S.: The case of visceral fat: argument for the defense. J. Clin. Invest., 2004, 113, 1530-1532.
28. Lafontan, M., Berlan, M.: Do regional differences in adipocyte biology provide new pathophysioiogical insights? Trends Pharmacol. Sci., 2003, 24, 276-283.
29. Magyar Diabetes Társaság Metabolikus Munkacsoportja: A metabolikus szindróma definíciója, diagnosztikai kritériumrendszere és szurése: Orv. Hetil., 2002, 143, 785-788.
30. Moitra, J., Mason, M. M., Olive, M. és mtsai: Life without white fat: a transgenic mouse. Genes Dev., 1998, 12, 3168-3181.
31. Montague, C. T., O'Rahilly, S.: The perils of portliness: causes and consequences of visceral adiposity. Diabetes. 2000, 49, 883-888.
32. Neel, J. V.: Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"? Am. J. Hum. Genet., 1962, 14, 353-362.
33. Nielsen, S., Guo, Z., Johnson, C. M. és mtsai: Splanchnic lipolysis in human obesity. J. Clin. Invest., 2004, 113, 1582-1588.
34. Peiris, A. N., Hennes, M. I., Evans, D. J. és mtsai: Relationship of anthropometric measurements of body fat distribution to metabolic profile in premenopausal women. Acta Med. Scand. Suppl., 1988, 723, 179-188.
35. Randle, P. J., Garland, P. B., Hales, C. N. és mtsai: The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet, 1963, 13, 785-789.
36. Ravussin, E., Smith, S. R.: Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and type 2 diabetes mellitus. Ann. N. Y. Acad. Sci., 2002, 967, 363-378.
37. Reaven, G. M.: Role of insulin resistance in human disease. Diabetes, 1988, 37, 1595-607.
38. Salans, L. B., Knittle, J. L., Hirsch, J.: Role of adipose cell size and adipose tissue insulin sensitivity in the carbohydrate intolerance of human obesity. J. Clin. Invest., 1968, 47, 53-165.
39. Seidell, J. C., Bouchard, C.: Visceral fat in relation to health: is it a major culprit or simply an innocent bystander? Intern. J. Obes., 1997, 21, 626-631.
40. Shulman, G. I.: Cellular mechanisms of insulin resistance. J. Clin. Invest., 2000, 106, 171-176.
41. Steppan, C. LM., Lazar, M. A.: Resistin and obesity-associated insulin resistance. Trends Endocrinol. Metab., 2002, 13, 18-23.
42. Stewart, P. M.: Tissue-specific Cushing's syndrome, 11beta-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action. Eur. J. Endocrinol., 2003, 149, 163-168.
43. Stulnig, T. M., Waldhausl, W.: 11beta-Hydroxysteroid dehydrogenase Type 1 in obesity and Type 2 diabetes. Diabetologia. 2004, 47, 1-11.
44. Stumvoll, M., Haring, H. U.: Glitazones: clinical effects and molecular mechanisms. Ann Med. 2002, 34, 217-224.
45. The IDF consensus worldwide definition of the metabolic syndrome. 1st International Congress on "Prediabetes" & the Metabolic Syndrome, 2005 April 13-16, Berlin [http://www.idf.org/webdata/docs/ IDF_Metasyndrome_definition.pdf]
46. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Cholesterol in Adults (Adult Treatment Panel III). JAMA, 2001, 285, 2486-2497.
47. Thomas, E. L., Saeed, N., Hajnal, J. V. és mtsai: Magnetic resonance imaging of total body fat. J. Appl. Physiol. 1998, 85, 1778-1785.
48. Unger, R. H.: Lipotoxic diseases. Ann. Rev. Med., 2002, 53, 319-336.
49. Vague, J.: The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am. J. Clin. Nutr, 1956, 4, 20-34.
50. Weyer, C., Foley, J. E., Bogardus, C. és mtsai: Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance. Diabetologia, 2000, 43, 1498-1506.